You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Finasteride; tadalafil - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for finasteride; tadalafil and what is the scope of patent protection?

Finasteride; tadalafil is the generic ingredient in two branded drugs marketed by Blue Water Biotech and Zydus Lifesciences, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for finasteride; tadalafil
US Patents:0
Tradenames:2
Applicants:2
NDAs:2
Finished Product Suppliers / Packagers: 1
Clinical Trials: 2
DailyMed Link:finasteride; tadalafil at DailyMed
Recent Clinical Trials for finasteride; tadalafil

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Vanderbilt University Medical CenterPhase 2
Eli Lilly and CompanyPhase 3

See all finasteride; tadalafil clinical trials

US Patents and Regulatory Information for finasteride; tadalafil

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Blue Water Biotech ENTADFI finasteride; tadalafil CAPSULE;ORAL 215423-001 Dec 9, 2021 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Zydus Lifesciences FINASTERIDE AND TADALAFIL finasteride; tadalafil CAPSULE;ORAL 218232-001 Mar 15, 2024 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Finasteride; tadalafil Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Finasteride and Tadalafil

Introduction to Finasteride and Tadalafil

Finasteride and tadalafil are two widely used medications with distinct therapeutic applications. Finasteride is primarily used to treat male pattern baldness and benign prostatic hyperplasia (BPH), while tadalafil is used to treat erectile dysfunction (ED), BPH, and pulmonary arterial hypertension.

Finasteride Market Dynamics

Market Size and Growth

The global finasteride market was valued at approximately USD 102.21 million in 2023 and is expected to grow to USD 128.77 million by 2032, exhibiting a CAGR of 2.8% during the forecast period[1][4][5].

Key Drivers

  • Increasing Prevalence of Hair Loss and BPH: The rising incidence of male pattern baldness and BPH are significant drivers. Approximately two-thirds of men are expected to experience hair loss by the age of 35, and nearly 90% of men above 80 years suffer from BPH[1][4][5].
  • Geriatric Population: The growing geriatric population is another key factor, as older men are more prone to BPH and hair loss[4][5].
  • R&D Activities: Continuous research and development in the pharmaceutical industry, particularly in emerging economies, are driving market growth[4][5].

Market Segmentation

  • Application: The market is segmented into prostate treatment, hair treatment, and others. The prostate treatment segment is expected to hold the largest share due to the high prevalence of BPH[4].
  • Distribution Channel: Online pharmacies are anticipated to witness the highest growth due to the increasing use of digital technology and online medical stores[4].

Regional Insights

  • Asia Pacific: This region is expected to hold the largest revenue share by 2036, driven by the growing penetration of finasteride in developing countries and the expansion of pharmaceutical companies' sales networks[4].
  • North America: This region is also expected to witness significant growth due to the rise in prevalence of male pattern baldness and advanced healthcare infrastructure[5].

Tadalafil Market Dynamics

Market Size and Growth

The global tadalafil market was valued at USD 6.25 billion in 2024 and is expected to grow to USD 17.00 billion by 2034, with a CAGR of 11.6% during the forecast period[2][3].

Key Drivers

  • Increasing Awareness of Men's Health: Growing awareness and acceptance of treatments for ED and BPH are driving the market. The aging population and the need for efficient treatment options are also significant factors[2][3].
  • Formulation Innovations: Advances in formulations, such as combination therapies and once-daily dosages, are improving patient adherence and satisfaction[3].

Market Segmentation

  • Application: Tadalafil is used for ED, BPH, and pulmonary arterial hypertension. The ED segment is particularly strong, especially in North America[2].
  • Region: North America dominates the market, followed by the Asia Pacific, which offers significant growth potential due to rising disposable incomes and urbanization[2].

Regional Insights

  • North America: This region is a developed market where tadalafil is well-known, especially for treating ED. Increased awareness campaigns and educational materials are boosting prescriptions[2].
  • Asia Pacific: This region offers a substantial potential market due to growing awareness of men's health issues, rising disposable incomes, and expanding urbanization[2].

Financial Trajectory for Finasteride

Revenue Projections

  • The finasteride market is projected to grow from USD 102.21 million in 2023 to USD 128.77 million by 2032, with a CAGR of 2.8%[1].
  • Another projection indicates the market will reach USD 154.82 million by 2036, growing at a CAGR of 2.7% from 2024 to 2036[4].

Impact of Pandemic

  • The market was negatively impacted during the COVID-19 pandemic due to disrupted global supply chains and delays in clinical trials[5].

Financial Trajectory for Tadalafil

Revenue Projections

  • The tadalafil market is expected to grow from USD 6.25 billion in 2024 to USD 17.00 billion by 2034, with a CAGR of 11.6%[2].
  • An alternative projection suggests the market will reach USD 4.8 billion by 2031, growing at a CAGR of 4.9% from 2024 to 2031[3].

Key Players

  • Major players in the tadalafil market include Glenmark Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Eli Lilly and Co. Pvt. Ltd., and others[2].

Challenges and Restraints

Finasteride

  • Side Effects: Potential side effects such as decreased libido and erectile dysfunction can act as market restraints[4].
  • Regulatory Issues: Regulatory frameworks and healthcare systems can influence market dynamics, particularly in regions with stringent regulations[5].

Tadalafil

  • Adverse Reactions: Possible adverse reactions are a significant market restraining factor[2].
  • Access to Healthcare: Limited access to healthcare facilities and specialists in certain regions can restrict market growth[2].

Future Outlook

Finasteride

  • The market is expected to benefit from increasing healthcare expenditure in emerging economies and the growing emphasis on physical appearance, particularly among young adults[4][5].

Tadalafil

  • The Asia Pacific region is anticipated to offer significant growth opportunities due to rising awareness of men's health issues and increasing disposable incomes[2].
"According to the American Cancer Society, in the year 2021, about 248,530 new cases of prostate cancer were estimated in the United States. Moreover, around 6 in 10 of the diagnosed cases belonged to men who were 65 years or older."[4]

Key Takeaways

  • Finasteride: The market is driven by the increasing prevalence of hair loss and BPH, with significant growth expected in the Asia Pacific region.
  • Tadalafil: The market is driven by growing awareness of men's health issues, formulation innovations, and strong demand in North America and the Asia Pacific.
  • Financial Trajectory: Both markets are expected to grow, with finasteride reaching USD 128.77 million by 2032 and tadalafil reaching USD 17.00 billion by 2034.
  • Challenges: Both markets face challenges such as potential side effects and limited access to healthcare in certain regions.

FAQs

1. What are the primary uses of finasteride and tadalafil?

  • Finasteride is primarily used to treat male pattern baldness and benign prostatic hyperplasia (BPH). Tadalafil is used to treat erectile dysfunction (ED), BPH, and pulmonary arterial hypertension.

2. What are the key drivers of the finasteride market?

  • The key drivers include the increasing prevalence of hair loss and BPH, the growing geriatric population, and ongoing R&D activities in the pharmaceutical industry.

3. How is the tadalafil market segmented?

  • The tadalafil market is segmented by purity, form, application, and region. The ED segment is particularly strong, especially in North America.

4. What are the regional insights for the finasteride market?

  • The Asia Pacific region is expected to hold the largest revenue share by 2036, driven by the growing penetration of finasteride in developing countries.

5. What are the potential challenges for the tadalafil market?

  • Potential challenges include adverse reactions and limited access to healthcare facilities and specialists in certain regions.

Sources:

  1. Polaris Market Research - Finasteride Market Statistics, Growth & Competitive Analysis 2032
  2. Prophecy Market Insights - Tadalafil Market Size Global Report, 2024 – 2034
  3. Market Research Intellect - Tadalafil Market Size and Projections - Market Research Intellect
  4. Research Nester - Finasteride Market Size & Share, Growth Report 2036
  5. Allied Market Research - Finasteride Market Statistics, Regional Analysis | Forecast - 2031

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.